Trial shows Huntington's drug could slow progress of disease
theguardian.com
theguardian.com
Godspeed to everybody working on this...with an emphasis on the “speed” part.
ISTR there are statistical techniques which can help, but even so, we're on for a 2-year trial in all likelihood. My neurologist was literally dancing in his chair. :)
It'll be interesting to see if the technique extends to other single-cause conditions.
The don’t want to dismiss the difference though.
Living longer is not automatically some magical gift.
http://www.cell.com/neuron/pdf/S0896-6273(12)00444-8.pdf
> To determine the distribution and cellular uptake of antisense oligonucleotides (ASOs) delivered by infusion into the CNS, an antibody that selectively recognizes the phosphorthioate backbone of the ASOs (see Figure S2 A for additional saline controls from the various brain regions) was used to probe coronal sections from the olfactory bulb to the cerebellum (see Figure S2B for schematic of sectioning and dissections). Following a two week infusion of the HuASO into nontransgenic animals, ASO accumulation was detected in the neurons of most brain regions, including the frontal cortex, striatum, thalamus, midbrain, brainstem, and cerebellum, with the exception of dense regions of white matter and cerebellar granule cells (Figure 2 A). ASOs were also present in neuronal nuclei, cell bodies and neurites, as determined by colocalization of accumulated ASOs with the neuronal marker NeuN (Figure 2B). ASOs also accumulated in nonneuronal cells, including glial fibrillary acidic protein (GFAP)-expressing astrocytes (Figure 2B)
[1] https://clinicaltrials.gov/ct2/show/NCT02519036?term=ionis&c...
[2] https://clinicaltrials.gov/ct2/results?cond=&term=ionis&cntr...